More Articles Back to Article
Novartis gains EU approval for MS treatment Mayzent
The European Commission approved Novartis' Mayzent, or siponimod, as a treatment for adults with active secondary progressive multiple sclerosis, providing this patient subpopulation a new treatment option. PMLive (UK) (1/21)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!